Novelion Therapeutics Inc. (NASDAQ:NVLN) Given a $9.00 Price Target by Royal Bank Of Canada Analysts

Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSE:QLT) has been given a $9.00 price target by equities researchers at Royal Bank Of Canada in a note issued to investors on Tuesday, August 8th. The firm presently has a “hold” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 20.00% from the company’s previous close.

Several other analysts also recently weighed in on NVLN. ValuEngine downgraded shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of Novelion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Bloom Burton restated an “accumulate” rating on shares of Novelion Therapeutics in a research report on Monday, June 19th.

Novelion Therapeutics (NASDAQ:NVLN) opened at 7.50 on Tuesday. The company’s 50-day moving average is $8.84 and its 200 day moving average is $9.77. The stock’s market capitalization is $139.50 million. Novelion Therapeutics has a 12-month low of $6.85 and a 12-month high of $13.80.

Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.04. The company had revenue of $40.90 million for the quarter, compared to analysts’ expectations of $36.86 million. On average, analysts predict that Novelion Therapeutics will post ($1.66) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/08/19/novelion-therapeutics-inc-nasdaqnvln-given-a-9-00-price-target-by-royal-bank-of-canada-analysts-updated.html.

Hedge funds have recently added to or reduced their stakes in the company. Stifel Financial Corp bought a new stake in Novelion Therapeutics during the first quarter worth approximately $107,000. JPMorgan Chase & Co. increased its stake in Novelion Therapeutics by 167.2% in the first quarter. JPMorgan Chase & Co. now owns 10,292 shares of the biotechnology company’s stock worth $110,000 after buying an additional 6,440 shares during the period. State of Wisconsin Investment Board bought a new stake in Novelion Therapeutics during the second quarter worth approximately $102,000. Franklin Resources Inc. increased its stake in Novelion Therapeutics by 4.2% in the second quarter. Franklin Resources Inc. now owns 12,798 shares of the biotechnology company’s stock worth $118,000 after buying an additional 511 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Novelion Therapeutics by 8,096.0% in the second quarter. The Manufacturers Life Insurance Company now owns 14,179 shares of the biotechnology company’s stock worth $130,000 after buying an additional 14,006 shares during the period. Institutional investors own 71.19% of the company’s stock.

Novelion Therapeutics Company Profile

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

What are top analysts saying about Novelion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novelion Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit